In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in ...

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below ...

In connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Good afternoon. And welcome to our third quarter call of 2018-19. My name is Kristian Villumsen, and I'm the CEO of Coloplast. I'm joined here by our CFO, Anders Lonning-Skovgaard and our Investor ...

Good morning to those of you here in the room, and also good morning to those of you joining us virtually today. On behalf of the Coloplast management team and on behalf of Investor Relations, I would ...

1 Day COLO.B 0.86% DJIA -2.08% S&P 500 -2.70% Health Care/Life Sciences -0.24% ...

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...